XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.3

Segment and Geographic Data (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

Segment Results
	Three Months				Nine Months
	2025		2024		2025		2024
MedSurg and Neurotechnology	$3,803		$3,324		$11,085		$9,636
Orthopaedics	2,254		2,170		6,860		6,523
Net sales	$6,057		$5,494		$17,945		$16,159
MedSurg and Neurotechnology	$1,426		$1,313		$4,162		$3,838
Orthopaedics	620		561		1,848		1,728
Cost of sales	$2,046		$1,874		$6,010		$5,566
MedSurg and Neurotechnology	$247		$205		$718		$594
Orthopaedics	132		136		399		406
Segment research, development and engineering expenses	$379		$341		$1,117		$1,000
MedSurg and Neurotechnology	$972		$780		$2,893		$2,318
Orthopaedics	742		760		2,332		2,267
Segment selling, general and administrative expenses	$1,714		$1,540		$5,225		$4,585
MedSurg and Neurotechnology	$56		$60		$171		$170
Orthopaedics	111		112		313		325
Segment depreciation and amortization	$167		$172		$484		$495
Corporate and Other	$48		$40		$127		$118
Amortization of intangible assets	189		159		543		467
Total depreciation and amortization	$404		$371		$1,154		$1,080
MedSurg and Neurotechnology	$1,102		$966		$3,141		$2,716
Orthopaedics	649		601		1,968		1,797
Segment operating income	$1,751		$1,567		$5,109		$4,513
Items not allocated to segments:
Corporate and Other	$(202)		$(211)		$(670)		$(676)
Inventory stepped up to fair value	(61)		(29)		(160)		(38)
Acquisition and integration-related charges	(39)		(48)		(302)		(49)
Amortization of intangible assets	(189)		(159)		(543)		(467)
Structural optimization and other special charges	(41)		(22)		(93)		(92)
Goodwill and other impairments	(73)		(2)		(163)		(21)
Medical device regulation	(11)		(13)		(30)		(41)
Recall-related matters	(1)		—		(56)		(22)
Regulatory and legal matters	—		1		(7)		1
Consolidated operating income	$1,134		$1,084		$3,085		$3,108

Segment Assets
	September 30		December 31
	2025		2024
Assets:
MedSurg and Neurotechnology	$27,280		$23,115
Orthopaedics	18,192		18,507
Total segment assets	$45,472		$41,622
Corporate and Other	1,585		1,349
Total assets	$47,057		$42,971

Sales and Other Financial Information by Business Segment

Segment Capital Spending	Nine Months
	2025		2024
Purchases of property, plant and equipment:
MedSurg and Neurotechnology	$153		$136
Orthopaedics	169		171
Total segment purchases of property, plant and equipment	$322		$307
Corporate and Other	171		182
Total purchases of property, plant and equipment	$493		$489

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration